ClinicalTrials.gg
CompletedNCT07950319Updated Nov 20, 2026

Exploring the Use of Fecal Microbiota Transplantation in Treating Diabetes-Related Constipation

An observational study in Functional Constipation (FC), Fecal Microbiota Transplantation and Type 2 Diabetes Mellitus (T2DM), sponsored by Shanghai 10th People's Hospital. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Shanghai 10th People's Hospital · Observational

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
30
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 913 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 229 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.

Enrollment
138th of 143
30 · median 556
Started
2020
with 50 others
Observational
143 of 913
56 open now
Registered
913th of 913
by date

Among the 913 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 138th largest by enrollment of the 143 observational ones that give a count, is one of 51 that started in 2020, is one of 143 observational ones, and was the 913th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

205 of the 913 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 373 (42%) set no upper age limit and 384 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 913 studies in Diabetes Mellitus, Type 2 with a site in China, or all of them as a file.
02

Study summary

This study aims to retrospectively evaluate the clinical effectiveness and safety of fecal microbiota transplantation (FMT) in treating patients with functional constipation (FC) who also have type 2 diabetes mellitus (T2DM). It analyzes changes in bowel function, glucose metabolism indicators, and gut microbiota structure before and after FMT, and further explores the relationship between donor-related microbiota remodeling, predicted microbial metabolic functions, and clinical outcomes.

03

Conditions studied

  • Functional Constipation (FC)
  • Fecal Microbiota Transplantation
  • Type 2 Diabetes Mellitus (T2DM)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults aged ≥18 years with Rome IV-diagnosed functional constipation complicated by T2DM who received FMT at a single center (2020-2024) and had complete data at baseline (FMT-0) and day 30 (FMT-30); exclusions were pregnancy, malignancy, severe comorbidity, immunosuppression, antibiotics/probiotics or prior FMT within 4 weeks, and incomplete records or loss to follow-up. A total of 30 patients were analyzed.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Clearly diagnosed with functional constipation.
  2. Clearly diagnosed with type 2 diabetes.
  3. Received FMT treatment between January 2020 and December 2024.
  4. Have clinical data before and after FMT treatment.
  5. Have stool samples before and after FMT treatment for gut microbiota analysis.

Exclusion criteria

Exclusion Criteria:

  1. Combined gastrointestinal .
  2. History of gastrointestinal surgery.
  3. Presence of megacolon.
  4. History of broad-spectrum antibiotic use.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
30 participants (actual)
Patient registry
No

Groups and cohorts

  • FMT-0 group

    FMT-0 is the baseline assessment immediately before the first FMT infusion. Data were retrieved retrospectively from electronic medical records. Each patient served as his or her own control.

  • FMT-30 group

    The same patients, assessed 30 days after completing the FMT course (primary efficacy time point), to compare pre- and post-treatment clinical indices and gut microbiota. FMT: oral vancomycin 500 mg twice daily for 3 days, then 2 L polyethylene glycol bowel cleansing, then frozen fecal suspension infused via nasojejunal tube once daily for 6 days.

06

What researchers measure

Primary outcomes

  1. Change in spontaneous bowel movement (SBM) frequency

    Compare the number of times patients have spontaneous bowel movements per week before FMT treatment and 30 days after treatment to assess improvement in constipation symptoms. Calculation formula: ΔSBM = SBM30 - SBM0. An increase in the number means more spontaneous bowel movements per week.

    Time frame: 30 days

  2. Fasting blood sugar (FPG) changes

    Compare patients' fasting blood glucose levels before FMT treatment and 30 days after treatment to evaluate changes in glucose metabolism indicators. Calculation formula: ΔFPG = FPG0 - FPG30. An increase in the value indicates a decrease in fasting blood glucose.

    Time frame: 30 days

07

Study locations

1 site
  • Shanghai Tenth People's Hospital
    Shanghai, Shanghai Municipality 200072, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in Dec 2024, 59 months.

Of 435 non-industry observational studies under Diabetes Mellitus, Type 2, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 96. This study's 59 months is above that.

Counting every sponsor, half of 605 studies reached it within 32 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2026
First posted
Nov 20, 2026
StartActual
Jan 1, 2020
Primary completionActual
Dec 31, 2024
CompletionActual
Oct 20, 2025
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07950319
Responsible party
Chen QiYi (Director of department, Shanghai 10th People's Hospital) — Principal investigator
First posted
Nov 20, 2026
Start date
Jan 1, 2020
Primary completion
Dec 31, 2024
Completion
Oct 20, 2025
Last update
Nov 20, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion